These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 24938496)

  • 1. Design and synthesis of 5-[(2-chloro-6-fluorophenyl)acetylamino]-3-(4-fluorophenyl)-4-(4-pyrimidinyl)isoxazole (AKP-001), a novel inhibitor of p38 MAP kinase with reduced side effects based on the antedrug concept.
    Hasumi K; Sato S; Saito T; Kato JY; Shirota K; Sato J; Suzuki H; Ohta S
    Bioorg Med Chem; 2014 Aug; 22(15):4162-76. PubMed ID: 24938496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of the disposition of a novel p38 MAPK inhibitor, AKP-001, and its metabolites in rats with a simple physiologically based pharmacokinetic model.
    Shirota K; Kaneko M; Sasaki M; Minato K; Fujikata A; Ohta S; Hisaka A; Suzuki H
    Drug Metab Dispos; 2015 Feb; 43(2):217-26. PubMed ID: 25422274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-inflammatory effect and selectivity profile of AS1940477, a novel and potent p38 mitogen-activated protein kinase inhibitor.
    Terajima M; Inoue T; Magari K; Yamazaki H; Higashi Y; Mizuhara H
    Eur J Pharmacol; 2013 Jan; 698(1-3):455-62. PubMed ID: 23183108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-based design, synthesis, and biological evaluation of imidazo[1,2-b]pyridazine-based p38 MAP kinase inhibitors.
    Kaieda A; Takahashi M; Takai T; Goto M; Miyazaki T; Hori Y; Unno S; Kawamoto T; Tanaka T; Itono S; Takagi T; Hamada T; Shirasaki M; Okada K; Snell G; Bragstad K; Sang BC; Uchikawa O; Miwatashi S
    Bioorg Med Chem; 2018 Feb; 26(3):647-660. PubMed ID: 29291937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The design and synthesis of novel alpha-ketoamide-based p38 MAP kinase inhibitors.
    Montalban AG; Boman E; Chang CD; Ceide SC; Dahl R; Dalesandro D; Delaet NG; Erb E; Ernst JT; Gibbs A; Kahl J; Kessler L; Lundström J; Miller S; Nakanishi H; Roberts E; Saiah E; Sullivan R; Wang Z; Larson CJ
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1772-7. PubMed ID: 18325768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors.
    Das J; Moquin RV; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2652-7. PubMed ID: 18359226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based de novo design and synthesis of aminothiazole-based p38 MAP kinase inhibitors.
    Park H; Lee S; Hong S
    Bioorg Med Chem Lett; 2015 Sep; 25(18):3784-7. PubMed ID: 26259807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Substituted isoxazoles as potent inhibitors of p38 MAP kinase.
    Laufer SA; Margutti S; Fritz MD
    ChemMedChem; 2006 Feb; 1(2):197-207. PubMed ID: 16892352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs).
    Burns CJ; Bourke DG; Andrau L; Bu X; Charman SA; Donohue AC; Fantino E; Farrugia M; Feutrill JT; Joffe M; Kling MR; Kurek M; Nero TL; Nguyen T; Palmer JT; Phillips I; Shackleford DM; Sikanyika H; Styles M; Su S; Treutlein H; Zeng J; Wilks AF
    Bioorg Med Chem Lett; 2009 Oct; 19(20):5887-92. PubMed ID: 19762238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biological evaluation of trisubstituted imidazole derivatives as inhibitors of p38alpha mitogen-activated protein kinase.
    Kim DK; Lim JH; Lee JA; Dewang PM
    Bioorg Med Chem Lett; 2008 Jul; 18(14):4006-10. PubMed ID: 18571921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and SAR of phenylamino-substituted 5,11-dihydro-dibenzo[a,d]cyclohepten-10-ones and 11H-dibenzo[b,f]oxepin-10-ones as p38 MAP kinase inhibitors.
    Dorn A; Schattel V; Laufer S
    Bioorg Med Chem Lett; 2010 May; 20(10):3074-7. PubMed ID: 20418099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continued exploration of the triazolopyridine scaffold as a platform for p38 MAP kinase inhibition.
    Jerome KD; Rucker PV; Xing L; Shieh HS; Baldus JE; Selness SR; Letavic MA; Braganza JF; McClure KF
    Bioorg Med Chem Lett; 2010 Jan; 20(2):469-73. PubMed ID: 19969459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-inflammatory properties of a novel N-phenyl pyridinone inhibitor of p38 mitogen-activated protein kinase: preclinical-to-clinical translation.
    Hope HR; Anderson GD; Burnette BL; Compton RP; Devraj RV; Hirsch JL; Keith RH; Li X; Mbalaviele G; Messing DM; Saabye MJ; Schindler JF; Selness SR; Stillwell LI; Webb EG; Zhang J; Monahan JB
    J Pharmacol Exp Ther; 2009 Dec; 331(3):882-95. PubMed ID: 19720877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of ML3403 ({4-[5-(4-fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-(1-phenylethyl)-amine), a 4-Pyridinylimidazole-type p38 mitogen-activated protein kinase inhibitor.
    Kammerer B; Scheible H; Albrecht W; Gleiter CH; Laufer S
    Drug Metab Dispos; 2007 Jun; 35(6):875-83. PubMed ID: 17344341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimization of alpha-ketoamide based p38 inhibitors through modifications to the region that binds to the allosteric site.
    Montalban AG; Boman E; Chang CD; Ceide SC; Dahl R; Dalesandro D; Delaet NG; Erb E; Ernst JT; Gibbs A; Kahl J; Kessler L; Kucharski J; Lum C; Lundström J; Miller S; Nakanishi H; Roberts E; Saiah E; Sullivan R; Urban J; Wang Z; Larson CJ
    Bioorg Med Chem Lett; 2010 Aug; 20(16):4819-24. PubMed ID: 20663667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Docking, synthesis and pharmacological activity of novel urea-derivatives designed as p38 MAPK inhibitors.
    de Oliveira Lopes R; Romeiro NC; de Lima CK; Louback da Silva L; de Miranda AL; Nascimento PG; Cunha FQ; Barreiro EJ; Lima LM
    Eur J Med Chem; 2012 Aug; 54():264-71. PubMed ID: 22647219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of N-substituted pyridinones as potent and selective inhibitors of p38 kinase.
    Selness SR; Devraj RV; Monahan JB; Boehm TL; Walker JK; Devadas B; Durley RC; Kurumbail R; Shieh H; Xing L; Hepperle M; Rucker PV; Jerome KD; Benson AG; Marrufo LD; Madsen HM; Hitchcock J; Owen TJ; Christie L; Promo MA; Hickory BS; Alvira E; Naing W; Blevis-Bal R
    Bioorg Med Chem Lett; 2009 Oct; 19(20):5851-6. PubMed ID: 19751974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and optimization of p38 inhibitors via computer-assisted drug design.
    Goldberg DR; Hao MH; Qian KC; Swinamer AD; Gao DA; Xiong Z; Sarko C; Berry A; Lord J; Magolda RL; Fadra T; Kroe RR; Kukulka A; Madwed JB; Martin L; Pargellis C; Skow D; Song JJ; Tan Z; Torcellini CA; Zimmitti CS; Yee NK; Moss N
    J Med Chem; 2007 Aug; 50(17):4016-26. PubMed ID: 17658737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.
    Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ
    ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, and biological evaluation of novel disubstituted dibenzosuberones as highly potent and selective inhibitors of p38 mitogen activated protein kinase.
    Koeberle SC; Fischer S; Schollmeyer D; Schattel V; Grütter C; Rauh D; Laufer SA
    J Med Chem; 2012 Jun; 55(12):5868-77. PubMed ID: 22676210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.